ADH-1: Interim Phase I/IIb data

Data from 20 evaluable patients in an ongoing, U.S. Phase I/IIb trial (AHX-01-007) showed that ADH-1 plus melphalan produced 10 complete responses at 3 months of follow-up. The trial is expected to en...